Company expects to submit deucrictibant IR capsule NDA to the U.S. FDA for the on-demand treatment of HAE attacks in 1H2026

RDP Pharma AG, a biotechnology company focused on next-generation protein degradation therapeutics, today announced a strategic research collaboration with the Experimental Drug Development Centre (EDDC), Singapore’s national platform for drug discovery and development, to jointly discover and develop a monovalent targeted protein degrader for anti-inflammatory therapies.

Navignostics announces the publication of a landmark study in Nature Medicine showing that its single-cell spatial proteomics technology contributed to improved outcomes in advanced melanoma patients, particularly those with no remaining standard treatment options.